Abstract:Background: Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. Objectives: To identify effective antibiotics for community acquired pneumonia (CAP) in children by comparing various antibiotics. Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 2) which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1966 to September 2009); and EMBASE (1990 to September 2009). Selection criteria: Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. Data collection and analysis: Two review authors independently extracted data from full articles of selected studies. Main results: There were 27 studies, which enroled 11,928 children, comparing multiple antibiotics. None compared antibiotic with placebo.For ambulatory treatment of non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (OR 0.92; 95% CI 0.58 to 1.47) and cure rates (OR 1.12; 95% CI 0.61 to 2.03). (Three studies involved 3952 children).In children hospitalised with severe CAP, oral amoxycillin compared with injectable penicillin or ampicillin had similar failure rates (OR 0.95; 95% CI 0.78 to 1.15). (Three studies involved 3942 children). Relapse rates were similar in the two groups (OR 1.28; 95% CI 0.34 to 4.82).In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamycin (OR 1.25; 95% CI 0.76 to 2.07). (One study involved 1116 children). Authors' conclusions: There were many studies with different methodologies investigating multiple antibiotics. For treatment of ambulatory patients with CAP, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. For severe pneumonia without hypoxia, oral amoxycillin may be an alternative to injectable penicillin in hospitalised children; however, for ambulatory treatment of such patients with oral antibiotics, more studies in community settings are required. For children hospitalised with severe and very severe CAP, penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are ceftrioxone, levofloxacin, co-amoxyclavulanic acid and cefuroxime. Until more studies are available, these can be used as a second-line therapy.There is a need for more studies with larger patient populations and similar methodologies to compare newer antibiotics.

Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis

Causative Agent Distribution and Antibiotic Therapy Assessment among Adult Patients with Community Acquired Pneumonia in Chinese Urban Population.

Combination Antibiotic Therapy Versus Monotherapy for Pseudomonas Aeruginosa Bacteraemia: A Meta-Analysis of Retrospective and Prospective Studies

The effects of empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: A systematic review and network meta-analysis of randomized controlled trials

Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults

Clinical evaluation on the empirical treatment of community acquired pneumonia

The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis

Nebulization of Antimicrobial Agents in Mechanically Ventilated Adults in 2017: an International Cross-Sectional Survey

Antibiotics for community-acquired pneumonia in children

Amoxicillin/metronidazole or scaling and root planing in the treatment of chronic periodontitis

Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study

Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis

Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis

Meta-analysis of the Effects of Combination Therapies of Β-Lactams and Fluoroquinolones or Macrolides in the Treatment of Community-Acquired Pneumonia.

Oral versus intravenous antibiotic treatment of moderate-to-severe community-acquired pneumonia: a propensity score matched study

Antibiotic Treatment of Pulmonary Infections: An Umbrella Review and Evidence Map

Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis

Analysis of Clinical Efficacy of Different Initial Antimicrobial Treatment in Healthcare Associated Pneumonia Patients in Emergency Department.

Improvement in Clinical and Economic Outcomes with Empiric Antibiotic Therapy Covering Atypical Pathogens for Community-Acquired Pneumonia Patients: a Multicenter Cohort Study.

No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia

Utilization of broad‐ versus narrow‐spectrum antibiotics for the treatment of outpatient community‐acquired pneumonia among adults in the United States